Healthier populations, everywhere

Support the secretariat of the WHO SAGE on immunization to synthesize evidence on select topics and draft meeting reports to facilitate policy-making.

MMGH is assisting the Inter-American Development Bank to prepare a rapid vaccine supply diagnostic study in support of work aimed at generating capacities in the countries that integrate PROSUR to produce vaccines for disease epidemics such as the COVID-19 pandemic. Through this project, MMGH is assessing existing vaccine manufacturing capacity in LAC region countries and regional demand and procurement mechanisms for COVID-19 and non-pandemic routine vaccines. A framework is also being developed to evaluate the optimal locations for investment to establish future vaccine manufacutring and fill and finish capabilities.

MMGH is supporting the US CDC and WHO to validate preliminary use cases and country archetypes previously developed for seasonal influenza vaccines. MMGH is conducting staekholder surveys, interviews and workshops with global influenza experts to validate the use cases and country archetypes for seasonal influenza vaccines developed in the earlier project. These activities are also supporting the development of an analytical framework that is applicable to any influenza vaccine profile (e.g., next-generation and universal influenza vaccines). The project will help to support the full value of seasonal influenza vaccine assessment, including key market dynamics analayses and roadmaps and action plans for current and future seasonal influenza vaccine use.

MMGH supported the WHO Immunisation Practices Advisory Committee (IPAC) Secretariat in revising the committee’s Terms of Reference (ToR). Based on information collected by MMGH during a series of in-depth stakeholder interviews and discussions, the functions of the committee were aligned with the new WHO structure and workplan as well as with those of other WHO global immunisation advisory groups.

MMGH supported the WHO Initiative for Vaccine Research (IVR) in facilitating a Strategic Advisory Group of Experts on Immunisation (SAGE) Working Group review of the scientific evidence and programmematic considerations supporting use of typhoid vaccines, with a focus on conjugate vaccines. The resulting vaccine recommendations were endorsed by the WHO SAGE in October 2017 and published as a WHO Position Paper.

MMGH supported the WHO in conducting a Bill & Melinda Gates Foundation supported project that investigated and analysed the status of maternal immunisation delivery strategies in low and middle-income countries. This included developing a typology of health systems in terms of how they deliver vaccines to pregnant women, and exploring approaches to improve country readiness for delivering new maternal vaccines, such as those against Respiratory Syncytial Virus and Group B Streptococcus.

Support WHO to draft and publish the position paper on pneumococcal conjugate vaccines in infants and children under 5 years of age.

MMGH supported the WHO Regional Office for Europe in drafting operational guidelines for programme managers to measure inequities in immunisation, with a focus on understanding the root causes and implementing solutions to achieve equity in access to immunisation.

MMGH supported the WHO Regional Office for Europe in developing a strategic framework to address the challenges faced by the middle-income countries in the region. This framework informed the development of a detailed roadmap to implement the recommended actions.

MMGH supported the WHO Regional Office for the Western Pacific in developing a guide for accelerating control of Japanese encephalitis (JE). The guide outlines regional targets, defines strategies and activities to accomplish these targets, and provides a framework for countries to develop national plans tailored to their situation. MMGH collaborated with the WHO Regional Office, country representatives and global experts to facilitate a meeting, draft the guidance and work towards an endorsed and funded strategy for JE control in the region.

MMGH supported the Eliminate Yellow Fever (EYE) Secretariat at WHO in streamlining programme governance and defining the general lines of action to serve as the foundation of a three-year multi-agency workplan. MMGH facilitated the interaction across the different partner agencies involved in the initiative and advised on the redesign of a streamlined governance structure. The streamlined governance structure should enable the initiative to have a more effective response to implementation challenges.

Support to the International Coordinating Group (ICG) for meningitis to improve access to vaccines for the international stockpile.

MMGH supported the WHO Department of Immunisation and Biologicals (IVB) in defining a logical framework to assess the barriers to access human papillomavirus (HPV) vaccine in middle-income countries, with a focus on affordability. The project, performed in collaboration with the Clinton Health Access Initiative (CHAI), led to the identification of a subset of countries that can benefit from specific technical assistance related to affordability and access.

Evaluation of the vaccine development ecosystem to identify areas for investment to support more efficient vaccine development for low-income countries and diseases with epidemic potential.

Supporting development of the 10-year strategic framework for measles and rubella.

MMGH supported Gavi, the Vaccine Alliance by documenting and synthesizing its key decisions related to the COVAX Facility and COVAX Advance Market Commitment (AMC). Activities include a desk review, key informant interviews, and thematic analysis. The conclusions from this work will serve to improve Gavi’s current learnings on the COVAX Facility and COVAX AMC design, governance, and operationalisation. Further information on the COVAX Facility and COVAX AMC can be found on the Gavi website.

Create a guide that focuses the allocation of resources (financial and human) towards answering the most pressing research questions that will have the most significant impact on our ability to control cholera.

Identify and understand the factors that accelerated COVID-19 vaccine development and authorization timelines and develop actions to replicate these factors for vaccines needed in low- and middle-income countries.

Assessing public and private sector perspectives to identify solutions to roadblocks preventing the development and implementation of the measles-rubella microarray patch in low- and middle-income countries.

Support the WHO European Regional Office to operationalize the European Immunization Agenda 2030 (EIA2030).